The ongoing COVID-19 pandemic has stimulated a lot of discussion around the issue of national governments rights to use patented technologies in dealing with public health emergencies. This webinar provides an analysis of national government’s powers to make use of patented inventions.

The speakers will examine the situation in three jurisdictions: Canada, where the COVID-19 Emergency Response Act (Bill C-13) received Royal Assent on March 25, 2020; the United Kingdom, where Government use of patented inventions is already part of the Patents Act; and South Africa, which has been very successful in bringing about pricing changes and increased distribution of medicines through use of an active citizenry, skilful interpretation of the Constitution.

Jennifer Marles (Oyen Wiggs, Canada) 

Jennifer is a partner of Oyen Wiggs.  Jennifer helps clients in the biotechnology, chemical and medical device industries build the value of their companies by securing patent protection in Canada, the United States, and beyond. Jennifer also assists clients with technology licensing, handling investor due diligence and evaluating their freedom to practise their technology.

John McKnight (Fellow – Spoor & Fisher, South Africa) 

 John specialises in the filing of applications in the chemical, biochemical and pharmaceutical fields, and related litigation. He also has experience in commercial transactions involving IP, including confidentiality, joint development, supply, licencing and technology transfer agreements.

Adrian Bradley (Fellow – Cleveland Scott York, UK) 

Adrian is a Partner at Cleveland Scott York. His practice focusses on healthcare, with specialisms in medical devices and pharmaceuticals. Having trained as a patent attorney in the pharmaceutical industry with Wyeth (now Pfizer), Adrian has a detailed knowledge of product lifecycle management in the sector


You must have a CIPA online account to book events online.  If you are a non-member and would like to attend, please email cpd@cipa.org.uk

Related Services